Printer Friendly

FDA APPROVES BRISTOL-MYERS SQUIBB'S STADOL NS NEW PRESCRIPTION NASAL SPRAY ANALGESIC

          FDA APPROVES BRISTOL-MYERS SQUIBB'S STADOL NS NEW
                 PRESCRIPTION NASAL SPRAY ANALGESIC
    NEW YORK, Dec. 19 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration has permitted the marketing of Stadol(R) NS (butorphanol tartrate), a unique prescription nasal spray analgesic.
    Stadol NS is indicated for the management of pain when the use of an opioid analgesic is appropriate.  In clinical trails, the effectiveness of Stadol NS has been demonstrated in a variety of pain models, including post-surgical pain and migraine headache pain.
    Butorphanol tartrate, the active ingredient in Stadol NS, is a potent analgesic that has been used extensively in an injectable form (Stadol) for more than 13 years.  Unlike other opioid analgesics such as Demerol or morphine, neither Stadol nor Stadol NS are controlled substances.  Stadol NS will provide the proven efficacy of butorphanol tartrate in a convenient, easy-to-administer nasal spray formulation.
    Shipment of Stadol NS will begin in early 1992.  The product will be marketed by Mead Johnson Laboratories, a division of Bristol-Myers Squibb serving the health care needs of women.  Mead Johnson Laboratories' product line includes Estrace, estrogen replacement therapy; Ovcon, an oral contraceptive; Vagistat-1, a vaginal antifungal treatment; and Natalins/R, prenatal vitamins.
    Bristol-Myers Squibb is a diversified health care company whose principal businesses are pharmaceuticals, consumer products, nutritionals and medical devices.  It is among the world's leading makers of cardiovascular, anticancer, anti-infective, central nervous system and dermatological drug therapies and diagnostic agents.
    -0-        12/19/91
    /CONTACT:  Janet Skidmore of Bristol-Myers Squibb, 609-921-5615, or after Dec. 31, 609-252-5615, or Brad Miles of Ted Klein & Co., 212-477-9007/
    (BMY) CO:  Bristol-Myers Squibb Company ST:  New York IN:  MTC SU: FC-SM -- NY070 -- 4044 12/19/91 15:40 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 19, 1991
Words:288
Previous Article:PENNSYLVANIA CHAMBER RELEASES STUDY ON TELECOMMUNICATIONS INDUSTRY
Next Article:EVEN IF TEMPERATURES PLUMMET, NJNG SAYS IT HAS ENOUGH GAS TO SERVE CUSTOMER NEEDS THIS WINTER
Topics:


Related Articles
UNIQUE NEW NASAL SPRAY FORM OF STADOL(R) ENTERS PRESCRIPTION PAIN RELIEF MARKET
BUTORPHANOL TARTRATE NASAL SPRAY OFFERS CONVENIENT THERAPY FOR TREATING MIGRAINE PAIN
MEAD JOHNSON LABS' OVCON(R) GOES 'GREEN'; LEADING ORAL CONTRACEPTIVE IS FIRST IN PRODUCT PORTFOLIO TO ADOPT ENVIRONMENTALLY SAFE PACKAGING
NASAL SPRAY ANALGESIC PAIN RELIEF BENEFITS COMPATIBLE WITH AHCPR PAIN MANAGEMENT GUIDELINES
BRISTOL-MYERS SQUIBB AND CEPHALON TO COPROMOTE STADOL NS; PAIN MANAGEMENT THERAPY IS FIRST PRODUCT REVENUE OPPORTUNITY FOR CEPHALON
BRISTOL-MYERS SQUIBB AND CEPHALON TO COPROMOTE STADOL NS; PAIN MANAGEMENT THERAPY IS FIRST PRODUCT REVENUE OPPORTUNITY FOR CEPHALON
BRISTOL-MYERS SQUIBB AND NEUROSEARCH TO COLLABORATE ON DEVELOPMENT OF DRUG FOR PARKINSON'S DISEASE
CEPHALON AND BRISTOL-MYERS SQUIBB EXPAND CO-PROMOTION AGREEMENT; CEPHALON TO CO-PROMOTE SERZONE TO NEUROLOGISTS
Nastech Reports First Quarter 1998 Results; Company Posts 4 Cents Profit on 115-Percent Revenue Gain
Nastech Announces Results of Pilot Phase I Trials Of a New Nasal Formulation for Acute Migraine.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters